New Oral Anticoagulants: Benefit-Risk Profile, Recurrence Rates, and Long-term Complications in Patients Treated for Established VTE
Clinical Pulmonary Medicine,  Clinical Article

Tapson V – New oral anticoagulants that do not require injections, routine coagulation monitoring, dose adjustment, or food restrictions are currently in development and/or recently approved and may enable physicians to better control anticoagulation therapy. Several Phase III trials have reported that the direct Factor Xa inhibitors rivaroxaban and apixaban and the direct thrombin inhibitor dabigatran are as effective as or superior to currently used low–molecular weight heparins or vitamin K antagonists.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Nursing

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Nursing Articles

Indexed Journals in Nursing: Journal of Advanced Nursing, Journal of Clinical Nursing, Nurse Education In Practicemore